CANFCan Fite Says Following Meetings With FDA And EMA, Co To Submit Protocol,Conduct 1 Pivotal Trial For Registration In Both Markets For Namodenoson https://www.benzinga.com/general/biotech/20/06/16178085/can-fite-says-following-meetings-with-fda-and-ema-co-to-submit-protocol-conduct-1-pivotal-trial-f https://www.businesswire.com/news/home/20200604005357/en/Can-Fite-Concludes-Successful-Meeting-European-Medicines-Agency Price Target $20.50